Published in Diabetes Care on July 17, 2013
Multifactorial Intervention in Type 2 Diabetes - Italy (MINDIT) | NCT01240070
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2014) 1.05
Multiple risk factor intervention reduces carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol (2014) 0.84
A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. Cardiovasc Diabetol (2015) 0.81
A Narrative Review of Diabetes Intervention Studies to Explore Diabetes Care Opportunities for Pharmacists. J Diabetes Res (2016) 0.75
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care (1993) 17.66
IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract (2011) 15.13
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia (2012) 10.74
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet (2009) 10.55
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53
Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med (2006) 7.32
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Design and analysis of group-randomized trials: a review of recent methodological developments. Am J Public Health (2004) 5.89
Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens (2011) 3.50
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J (2011) 2.29
Effect of the quality and outcomes framework on diabetes care in the United Kingdom: retrospective cohort study. BMJ (2009) 2.25
Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. Diabetologia (2006) 1.65
Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract (2011) 1.62
EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil (2010) 1.58
Randomized trial of quality improvement intervention to improve diabetes care in primary care settings. Diabetes Care (2005) 1.57
Impact of pay for performance on inequalities in health care: systematic review. J Health Serv Res Policy (2010) 1.29
Highlights from "Italian Standards of care for Diabetes Mellitus 2009-2010". Nutr Metab Cardiovasc Dis (2010) 1.25
Women show worse control of type 2 diabetes and cardiovascular disease risk factors than men: results from the MIND.IT Study Group of the Italian Society of Diabetology. Nutr Metab Cardiovasc Dis (2012) 1.12
Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Intern Med (2008) 1.12
Four-year impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics: the AMD-Annals initiative. Diabet Med (2010) 1.08
Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med (2007) 1.08
Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type 2 diabetes mellitus: a cluster randomized controlled trial. Diabet Med (2012) 1.06
Role of organizational factors in poor blood pressure control in patients with type 2 diabetes: the QuED Study Group--quality of care and outcomes in type 2 diabetes. Arch Intern Med (2003) 0.93
The clinical reality of guidelines for primary prevention of cardiovascular disease in type 2 diabetes in Italy. Atherosclerosis (2008) 0.92
Population based absolute and relative survival to 1 year of people with diabetes following a myocardial infarction: a cohort study using hospital admissions data. BMC Public Health (2010) 0.90
[Guidelines for cardiovascular prevention in diabetic patients]. Ital Heart J Suppl (2002) 0.78
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension (2012) 5.60
Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med (2010) 4.40
Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension (2004) 4.38
Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes (2008) 4.05
Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation. Hypertension (2007) 2.63
Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension (2005) 2.54
Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. Diabetes Care (2005) 2.26
Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem (2007) 2.20
Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjects. Diabetes Care (2003) 2.12
Pancreatic elastase-1 in stools, a marker of exocrine pancreas function, correlates with both residual beta-cell secretion and metabolic control in type 1 diabetic subjects. Diabetes Care (2004) 2.07
Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling. J Am Coll Cardiol (2006) 2.02
Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens (2007) 1.97
Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab (2002) 1.95
Development and validation of a food frequency questionnaire for the assessment of dietary total antioxidant capacity. J Nutr (2007) 1.71
Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation (2003) 1.63
Dietary glycemic index and liver steatosis. Am J Clin Nutr (2006) 1.59
Prognostic significance of isolated, non-specific left ventricular repolarization abnormalities in hypertension. J Hypertens (2004) 1.56
Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care (2011) 1.53
Deterioration of insulin sensitivity and glucose effectiveness with age and hypertension. Am J Hypertens (2006) 1.50
Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin A preliminary echocardiographic study. Atherosclerosis (2007) 1.50
Evaluation of a simple policy for pre- and post-prandial blood glucose self-monitoring in people with type 2 diabetes not on insulin. Diabetes Res Clin Pract (2009) 1.47
Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J (2009) 1.47
Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. Am J Hypertens (2007) 1.43
Comparative evaluation of simple indices of insulin resistance. Metabolism (2004) 1.42
High glucose rapidly activates the nitric oxide/cyclic nucleotide pathway in human platelets via an osmotic mechanism. Thromb Haemost (2005) 1.42
The IMPROVE study--a multinational, multicentre, observational study in type 2 diabetes: results from the Italian cohort. Acta Biomed (2010) 1.41
Blood pressure lowering in the oldest old. J Hypertens (2010) 1.40
The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens (2009) 1.38
Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol (2013) 1.33
HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care (2013) 1.31
Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens (2011) 1.26
Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension (2009) 1.16
Masked hypertension: evaluation, prognosis, and treatment. Am J Hypertens (2010) 1.12
Food selection based on total antioxidant capacity can modify antioxidant intake, systemic inflammation, and liver function without altering markers of oxidative stress. Am J Clin Nutr (2008) 1.12
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation provides a better definition of cardiovascular burden associated with CKD than the Modification of Diet in Renal Disease (MDRD) Study formula in subjects with type 2 diabetes. Atherosclerosis (2011) 1.11
Changing the treatment paradigm for type 2 diabetes. Diabetes Care (2009) 1.10
Total antioxidant capacity of the diet is inversely and independently related to plasma concentration of high-sensitivity C-reactive protein in adult Italian subjects. Br J Nutr (2005) 1.08
Pleiotropic effects of GIP on islet function involve osteopontin. Diabetes (2011) 1.08
Contribution of the ABP-International study to the definition of night-time tachycardia. J Hypertens (2014) 1.07
Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care (2012) 1.06
Insulin is required for prandial ghrelin suppression in humans. Diabetes (2003) 1.05
Adverse drug events as a cause of hospitalization in older adults. Drug Saf (2012) 1.05
Mitochondrial DNA backgrounds might modulate diabetes complications rather than T2DM as a whole. PLoS One (2011) 1.04
Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings. J Hypertens (2014) 1.04
Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. Nutr Metab Cardiovasc Dis (2005) 1.03
Incidence of type 1 and type 2 diabetes in adults aged 30-49 years: the population-based registry in the province of Turin, Italy. Diabetes Care (2005) 1.01
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia. Diabetes (2002) 1.01
Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. Circ Cardiovasc Genet (2011) 0.99
Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens (2010) 0.98
Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol (2002) 0.97
Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens (2014) 0.96
Left ventricular function in normotensive young adults with well-controlled type 1 diabetes mellitus. Am J Cardiol (2006) 0.95
The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol (2010) 0.94
Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag (2009) 0.94
Centenarians as super-controls to assess the biological relevance of genetic risk factors for common age-related diseases: a proof of principle on type 2 diabetes. Aging (Albany NY) (2013) 0.94
Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metabolism (2009) 0.94
Treating the metabolic syndrome. Expert Rev Cardiovasc Ther (2007) 0.93
Clinically driven semi-supervised class discovery in gene expression data. Bioinformatics (2008) 0.93
Primary prevention of cardiovascular disease in people with dysglycemia. Diabetes Care (2008) 0.93
Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab (2007) 0.92
Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol (2014) 0.92
Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: influence of insulin resistance and oxidative stress. Atherosclerosis (2011) 0.91
Dietary antioxidants and glucose metabolism. Curr Opin Clin Nutr Metab Care (2008) 0.91
Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. J Am Geriatr Soc (2013) 0.91
Improved cardiovascular risk stratification by a simple ECG index in hypertension. Am J Hypertens (2003) 0.90
The increase in plasma PAI-1 associated with insulin resistance may be mediated by the presence of hepatic steatosis. Atherosclerosis (2009) 0.90
The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag (2008) 0.90
New-onset diabetes, antihypertensive treatment, and outcome. Hypertension (2007) 0.90
Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm (2010) 0.90
Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance. PLoS One (2012) 0.90
Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. J Hypertens (2002) 0.90
Interaction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome. Obesity (Silver Spring) (2007) 0.90
Paraoxonase 1: genetics and activities during aging. Rejuvenation Res (2008) 0.89
Relation of plasma insulin levels to forearm flow-mediated dilatation in healthy volunteers. Am J Cardiol (2006) 0.89
Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis (2010) 0.88
Metabolic syndrome and vascular alterations in normotensive subjects at risk of diabetes mellitus. Hypertension (2007) 0.88
Quality of diabetes care in Italy: information from a large population-based multiregional observatory (ARNO diabetes). Diabetes Care (2012) 0.88
Role of NMDA receptor in homocysteine-induced activation of mitogen-activated protein kinase and phosphatidyl inositol 3-kinase pathways in cultured human vascular smooth muscle cells. Thromb Res (2009) 0.88
Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur J Endocrinol (2003) 0.87
Molecular characterization of nitrite reductase gene (aniA) and gene product in Neisseria meningitidis isolates: is aniA essential for meningococcal survival? IUBMB Life (2008) 0.87
Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. Curr Cardiol Rep (2012) 0.87
Circulating ghrelin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 0.87
Hyperglycemia and vascular metabolic memory: truth or fiction? Curr Diab Rep (2013) 0.87
Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol (2013) 0.86
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care (2009) 0.86
Mutual interactions between depression/quality of life and adherence to a multidisciplinary lifestyle intervention in obesity. J Clin Endocrinol Metab (2012) 0.86
The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents. Thromb Res (2004) 0.86
White-coat hypertension in adults. Blood Press Monit (2005) 0.86